AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06228612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vacuum therapy VT and maxillary stabilization splint (MSS)
Description: vacuum therapy VT and maxillary stabilization splint (MSS): both Basic vacuum therapy and maxillary stabilization splint :Procedures were the same as in group I and II.
Study NCT06545487 — intervention group
Intervention type: OTHER
Intervention: BLOOD SAMPLE
Description: BLOOD ANALYTICS IN SEVERAL PARAMETERS
Study NCT05700474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient behavioral health care
Description: Participation will include clinical assessment and outpatient behavioral health services, case management, individual and group counseling, peer support, case management, and education regarding behavioral health and medical care
Study NCT04887402 — intervention group
Intervention type: DRUG
Intervention: Clomiphene Citrate
Description: All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles >10mm, follow up till ovulation
Study NCT05379101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute Walk Test
Description: A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
Study NCT05194254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-ET
Description: coupled fMRI and Eye Tracking tools
Study NCT05194254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI-ET
Description: coupled fMRI and Eye Tracking tools
Study NCT06548763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 1.4mg/㎡, orally administered, d1-5
Study NCT06548763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, intravenous drip, d1, q3w
Study NCT05798845 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+LDRT
Description: primary tumor SBRT, DT: 24Gy/3Fx, d1-3; positive lymph nodes LDRT, DT: 2Gy/4Fx, d1-4, d22-25 (2 cycles)
Study NCT05798845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: toripalimab 240mg ivgtt d5, d26 (2 cycles)
Study NCT05798845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
Study NCT05798845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: toripalimab 240mg ivgtt d1, d22 (2 cycles)
Study NCT06549400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mexiletine granules for prolonged-release oral suspension
Description: Mexiletine PR
Study NCT04180904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet 1
Description: Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
Study NCT05361629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional steroid administration
Description: Treatment by administering steroids into the lesion
Study NCT05361629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative cavity steroid administration
Description: Treatment by administering steroids into the surgical cavity
Study NCT04180904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet 2
Description: This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
Study NCT05280093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure ISOLATOR Synergy Surgical Ablation System
Description: Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
Study NCT04343924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scuba diving activities
Description: The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
Study NCT04343924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality activities
Description: The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
Study NCT04674566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-101
Description: Administered intravenously (IV) single dose
Study NCT04674566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered intravenously (IV) single dose
Study NCT06549140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality exercise program
Description: Participants enrolled in an organized exercise program based on two weekly sessions of 45 to 60 minutes each for 12 weeks: one traditional session (group session) and one augmented reality (AR) session (individual session), both supervised by sports and exercise professionals. The AR session was designed to provide an entire exercise session targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time, decision-making, and memory).
Study NCT06549140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise program
Description: Participants enrolled in a traditional organized exercise program (group sessions) based on two weekly sessions of 45 to 60 minutes each for 12 weeks. These sessions are supervised by sports and exercise professionals, targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time and decision-making).
Study NCT05340985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH)D3
Description: calcifediol
Study NCT05340985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Cholecalciferol
Study NCT05319236 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gabi System
Description: See arm description
Study NCT06548659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: screen-based simulation
Description: Randomization took place among 198 people. The intervention group was given training on pediatric medication administration through screen-based simulation.
Study NCT04438447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: parenteral feeding
Description: A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation
Study NCT04438447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: parenteral feeding
Description: A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation
Study NCT06549010 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Perimetric test
Description: This study aims to evaluate a novel head-mounted perimeter against the HFA as an alternative method of VF testing. This new perimeter uses a Virtual Reality (VR) headset and a gamified version of VF testing to assess the visual function of healthy eyes and patients.
Study NCT05594745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast Ophthalmic
Description: eyedrop
Study NCT05594745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Free
Description: eyedrop
Study NCT05594745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiflow
Description: thermal pulsation
Study NCT06147726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity position matching exercises in virtual reality
Description: In addition to conventional treatment approaches for 20 minutes 2 days a week for 8 weeks, joint positioning exercises (4 different game sequences of 4 minutes, 1 minute rest between each sequence, total 20 minutes) designed specifically for the individual's existing range of motion will be applied to the VR group.
Study NCT06147726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises
Study NCT06384911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives Program
Description: Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.
Study NCT04739696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEPRR
Description: Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
Study NCT04739696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pep-Pal
Description: Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
Study NCT06774937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his
Description: Thorough clinical examination:~1. General examination including general look, vital signs and anthropometric measurements.~2. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) \[36\] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible).
Study NCT06774937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EMG ,rNST,Ach R antibodies & thyroid function
Description: C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible).
Study NCT06773286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Stimulation
Description: Participants will receive activity-based training (ABT) while receiving concomitant, active spinal stimulation (scTS) applied at the cervical and thoracic spinal segments over the dorsal skin with optimized and customized stimulation parameters. Round self-adhesive electrodes will be placed over the skin at the midline of spinous processes as cathodes and a pair of rectangular anodes electrodes will be placed over the anterior iliac crests of the pelvis. The stimulation waveform is rectangular pulse with 1-ms duration filled with a carrier frequency of 5kHz. Target simulation will be sub-threshold for UE muscle activation and verified by the absence of visible muscle contraction. The stimulation parameters will be adjusted as needed throughout the intervention course based on the participant's performance and comfort level. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
Study NCT06773286 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham-control group will go through ABT paired with sham stimulation to control for placebo effects associated with the perception of scTS. Stimulation will be delivered at one cervical location. No stimulation mapping procedure will be performed. During the training session, the stimulation intensity will be briefly ramped up to a level at which the participants report perceiving the stimulation, and then ramped down to 0mA at both the start and the end of session. The stimulator and electrodes will remain attached to the participant while receiving ABT training. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
Study NCT06773286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training only
Description: articipants in ABT group will receive ABT only. ABT will concentrate on activities of gross UE movement, grasping, pinching, gross and fine motor skill. The hand grasp task will focus on grasping objects with different shapes and weights (i.e. weighted container and tennis ball) and placing/removing them from small storage container; the pinch task involves picking up, translating, and releasing small objects with varied sizes (i.e. blocks, dices, marble balls, nuts, etc.). The training therapist selects tasks based on participant's level of impairment and individual goals. The dosage of ABT will be 30 minutes/session, with approximately 15 minutes allocated on each side.
Study NCT06774209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: three kinds of examinations
Description: Following the enrollment of patients, both Gallium-68 labeled Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography (68Ga-FAPI-04 PET/CT) and Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) scans are carried out. Additionally, within a one-week interval before and after the aforementioned examinations, Fluorine-18 labeled Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is performed on the same cohort of patients.
Study NCT06773754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Five-days-On and Two-days-Off
Description: Take Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir alafenamide five days a week (Five-days-On and Two-days-Off)
Study NCT06181344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCR screening and referral program
Description: Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
Study NCT05732194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution
Study NCT05732194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT04756713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine curettage
Description: Manual or electric vacuum aspiration under ultrasound guidance.
Study NCT04756713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
Study NCT04803760 — intervention group
Intervention type: OTHER
Intervention: A self-administered questionnaire
Description: A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
Study NCT06578104 — intervention group
Intervention type: DEVICE
Intervention: PulseSelect™ PFA system
Description: Ablation using the PulseSelect™ PFA system
Study NCT05655377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitMi PD
Description: Exercise using the motion sensing devices and a tablet computer
Study NCT06498934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: Stimulation of the dentate nucleus that is paired with upper limb rehabilitation movements.
Study NCT06498934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke
Study NCT06770309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silkworm pupa powder
Description: Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
Study NCT06770309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
Study NCT06774820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-blocking tenodesis
Description: the LHB tendon is detached from its origin in the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate later localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
Study NCT06498934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke
Study NCT06774820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic tenodesis
Description: LHB tendon is detached from its origin, and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-lasso loop tenodesis technique. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
Study NCT06771401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cervical mucus sampling
Description: Monitoring of menstrual cycle will be conducted in the follicular, ovulatory and luteal phases during which cervical mucus, serum and urine samples will be collected and pelvic ultrasound scans performed (3-5 ultrasound scans/samples within the cycle).
Study NCT06771167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Community Resilience Program (BCR)
Description: To improve CHW resilience and wellbeing, during each BCR cycle, the 6 participating CBOs will send groups of four to six CHWs to six virtual, hour-long, evidence-based interactive workshops (48-72 CHWs over the 2 cycles).
Study NCT05135832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes regarding symptoms and health-related quality of life
Description: Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.~The supportive care (including drugs) is similar in the two treatment arms except for the use of electronic patient-reported outcomes.
Study NCT04493892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure